The oxetane ring in Taxol

Journal of Organic Chemistry

Volumn 65, Issue 4, 2000, Pages 1059-1068

  Wang, Minmin ^a   Cornett, Ben ^a   Nettles, Jim ^a   Liotta, Dennis C ^a   Snyder, James P ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ARTICLE; COMPLEX FORMATION; DRUG ISOLATION; DRUG SYNTHESIS; HYDROPHOBICITY; LIGAND BINDING; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; ETHERS, CYCLIC; HYDROGEN BONDING; MACROLIDES; MODELS, MOLECULAR; PACLITAXEL; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS; TUBULIN;

EID: 0034712232     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo9916075     Document Type: Article

References (77)

1. (a) Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. J. Am. Chem. Soc. 1971, 93, 2325-2327.
2. (b) Taxol is a registered trademark of Bristol-Myers Squibb Co., Princeton, NJ.
3. Bissery, M.-C.; Guénard, D.; Guéritte-Voegelein, F.; Lavelle, F. Cancer Res. 1991, 51, 4845-4852.
4. (a) Greco, F. A.; Thomas, M.; Hainsworth, J. D. Cancer J. Sci. Am. 1999, 5, 179-191.
5. (b) Perez, E. A. Semin. Oncol. 1999, 26, 21-26.
6. (c) McGuire, W. P.; Ozols, R. F. Semin. Oncol. 1998, 25, 340-348; 25, 707.
7. (c) McGuire, W. P.; Ozols, R. F. Semin. Oncol. 1998, 25, 340-348; 25, 707.
8. See, however: Snyder, J. P.; Nevins, N.; Cicero, D. O.; Jansen, J. J. Am. Chem. Soc. 2000, 122, 724-725.
9. (a) Fenoglio, I.; Nano, G. M.; Vander Velde, D. G.; Appendino, G. Tetrahedron Lett. 1996, 37, 3203-3206.
10. (b) Marder-Karsenti, R.; Dubois, J.; Bricard, L.; Guénard, D.; Guéritte-Voegelein, F. J. Org. Chem. 1997, 62, 6631-6637.
11. (a) Gunatilaka, A. A. L.; Ramdayal, F. D.; Sarragiotto, M. H.; Kingston, D. G. I. J. Org. Chem. 1999, 64, 2694-2703.
12. (b) Guénard, D.; Guéritte-Voegelein, F. Private communication.
13. (a) Kingston, D. G.; Magri, N. F.; Jitrangsri, C. In New Trends in Natural Product Chemistry; Rahman, A., Quesne, L., Eds.; Elsevier: Amsterdam, 1986; Vol. 26, pp 219-235.
14. (b) Samaranayake, G.; Magri, N. F.; Jitrangeri, C.; Kingston, D. G. I. J. Org. Chem. 1991, 56, 5114-5119.
15. (c) Wahl, A.; Guéritte-Voegelein, F.; Guénard, D.; Le Goff, M.-T.; Potier, P. Tetrahedron 1992, 48, 6965-6974.
16. (d) Chen, S.-H.; Huang, S.; Wei, J.; Farina, V. Tetrahedron 1993, 49, 2805-2828.
17. (e) Baccatin oxetane ring opening was also reported previously: Guéritte-Voegelein, F.; Guénard, D.; Potier, P. J. Nat. Prod 1987, 50, 9-18.
18. Appendino, G.; Danieli, B.; Jakupovic, J.; Belloro, E.; Scambia, G.; Bombardelli, E. Tetrahedron Lett. 1997, 38, 4273-4276.
19. Nicolaou, K. C.; Claiborne, C. F.; Nantermet, P. G.; Couladouros, E. A.; Sorensen, E. J. J. Am. Chem. Soc. 1994, 116, 1591-1592.
20. Shintani, Y.; Tanaka, T.; Nozaki, Y. Cancer Chemother. Pharmacol. 1997, 40, 513-520.
21. Klar, U.; Graf, H.; Schenk, O.; Röhr, B.; Schulz, H. Bioorg. Med. Chem. Lett. 1998, 8, 1397-1402.
22. Wang, M.; Xia, X.; Kim, Y.; Hwang, D.; Jansen, J. M.; Botta, M.; Liotta, D. C.; Snyder, J. P. Org. Lett. 1999, 1, 43-46.
23. Zbinden P.; Dobler, M.; Folkers, G.; Vedani, A. Quant. Struct. Act. Relat. 1998, 17, 122-130.
24. A novel T-shaped conformation of Taxol resides in the largely hydrophobic β-tubulin binding pocket: Snyder, J. P.; Nettles, J.; Cornett, B.; Downing, K.; Nogales, E. Submitted for publication.
25. Nogales, E.; Wolf, S. G.; Downing, K. H. Nature 1998, 391, 199-203.
26. 14 Insofar as the present study is concerned, the two models differ significantly in the oxetane H-bond donor; Arg for the minireceptor, Thr for the protein-ligand complex. The former was chosen prior to knowledge of the 3-D character of the β-tubulin structure. The next generation anti-tubulin minireceptor will rectify this and other points of difference.
27. The Cambridge Structural Database: http://www.ccdc.cam.ac.uk/ prods/csd.html.
28. Appendino, G.; Gariboldi, P.; Gabetta, B.; Pace, R.; Bombardelli, E.; Viterbo, D. J. Chem. Soc., Perkin Trans. 1 1992, 2925-2929.
29. Farina, V.; Huang, S. Tetrahedron Lett. 1992, 33, 3979-3982.
30. Blaney, J. M.; Weiner, P.; Dearing, A.; Kollman, P.; Jorgensen, E.; Oatley, S.; Burridge, J.; Blake, C. J. Am. Chem. Soc. 1982, 104, 6424-6434.
31. Vedani, A.; Zbinden, P.; Snyder, J. P.; Greenidge, P. A. J. Am. Chem. Soc. 1995, 117, 4987-4994.
32. (a) Andrews, P. R.; Craik, D. J.; Martin, J. L. J. Med. Chem. 1984, 27, 1648-1657.
33. (b) Searle, M. S.; Williams, D. H. J. Am. Chem. Soc. 1992, 114, 10690-10697.
34. Cramer, C. J.; Truhlar, D. G. J. Am. Chem. Soc. 1991, 113, 8305-8311; 9901.
35. See the Supporting Information for: Hawkins, G. D.; Cramer, C. J.; Truhlar, D. G. J. Phys. Chem. 1996, 100, 19824-19839.
36. Dubois, J.; Thoret, S.; Guénard, D.; Guéritte, F. Submitted.
37. Kingston, D. G. I. In Taxane Anticancer Agents; Georg, G. I., Chen, T. T., Ojima, I., Vyas, D. M., Eds.; ACS Symposium Series 583; American Chemical Society: Washington, DC, 1995; pp 207-208.
38. Chen, S.-H.; Farina, V. In Taxane Anticancer Agents; Georg, G. I., Chen, T. T., Ojima, I., Vyas, D. M., Eds.; ACS Symposium Series 583; American Chemical Society: Washington, DC, 1995; pp 257-259.
39. Guéritte-Voegelein, F.; Guénard, D.; Dubois, J.; Wahl, A.; Marder, R.; Müller, R.; Lund, M.; Bricard, L.; Potier, P. In Taxane Anticancer Agents; Georg, G. I., Chen, T. T., Ojima, I., Vyas, D. M., Eds.; ACS Symposium Series 583; American Chemical Society: Washington, DC, 1995; pp 195-197.
40. Boge, T. C.; Hepperle, M.; Vander Velde, D. G.; Gunn, C. W.; Grunewald, G. L.; Georg, G. I. Bioorg. Med. Chem. Lett. 1999, 9, 3041-3046.
41. Appendino, G.; Danieli, B.; Jakupovic, J.; Belloro, E.; Scambia, G.; Bombardelli, E. Terahedron Lett. 1997, 38, 4273-4276.
42. Ojima, I.; Duclos, O.; Kuduk, S. D.; Sun, C.-M.; Slater, J. C.; Lavelle, F.; Veith, J. M.; Bernacki, R. J. Bioorg. Med. Chem. Lett. 1994, 4, 2631-2634.
43. Bombardelli, E.; Riva, A. In Virtual Activity, Real Pharmacology; Verotta, L., Ed.; Research Signpost: Trivandrum 1997; pp 61-83.
44. Distefano, M.; Scambia, G.; Ferlini, C.; Gallo, D.; De Vincenzo, R.; Filippini, P.; Riva, A.; Bombardelli, E.; Mancuso, S. Anti-Cancer Drug Des. 1998, 13, 489-499.
45. (a) Boge, T. C.; Himes, R. H.; Vander Velde, D. G.; Georg, G. I. J. Med. Chem. 1994, 37, 3337-3343.
46. (b) Ojima, I.; Kuduk, S. D.; Pera, P.; Veith, J. M.; Bernacki, R. J. J. Med. Chem. 1997, 40, 279-285.
47. Ojima, I.; Slater, J. C.; Pera, P.; Veith, J. M.; Abouabdellah, A.; Bégue, J.-P.; Bernacki, R. J. Bioorg. Med. Chem. Lett. 1997, 7, 133-128.
48. The free energies of aqueous solvation for benzene and 2-methylpropane are -0.87 and 2.3 kcal/mol, respectively; cf. ref 22.
49. (a) Blechert, S.; Kleine Klausing, A. Angew. Chem., Int. Ed. Engl. 1991, 30, 412-414.
50. (b) Blechert, S.; Jansen, R.; Velder, J. Tetrahedron 1994, 50, 9649-9656.
51. Nicolaou, K. C. (Scripps Institute), private communication.
52. Klar, U. (Schering AG), private communication.
53. (a) Kirikae, T.; Ojima, I.; Kirkae, F.; Ma, Z.; Kuduk, S. D.; Slater, J. C.; Takeuchi, C. S.; Bounaud, P.-Y.; Nakano, M. Biochem. Biophys. Res. Comm. 1996, 227, 227-235.
54. (b) Lee, L.-F.; Haskill, J. S.; Mukaida, N.; Matsushima, K.; Ting, J. P.-Y. Mol. Cell. Biol. 1997, 17, 5097-5105.
55. (c) Moos, P. J.; Fitzpatrick, F. A. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 3896-3901.
56. (a) Aime-Sempe, C.; Kitada, S.; Reed, J. C. Blood 1996, S-1, 88, 805.
57. (b) Leiu, C. H.; Chang, Y.-N.; Lai, Y.-K. Biochem. Pharmacol. 1997, 53, 1587-1596.
58. (c) Rodi, D. J.; Janes, R. W.; Sanganee, H. J.; Holton, R. A.; Wallace, B. A.; Makowski, L. J. Mol. Biol. 1999, 285, 197-203.
59. Blagosklonny, M. V.; Fojo, T. Int. J. Cancer 1999, 83, 151-156.
60. (a) Shapiro, A. B.; Ling, V. Acta Physiol. Scand. Suppl. 1998, 643, 227-234.
61. (b) Eytan, G. D.; Kuchel, P. W. Int. Rev. Cytol. 1999, 190, 175-250.
62. (c) Hendrikse, N. H.; Franssen, E. J.; van der Graaf, W. T.; Vaalburg, W.; de Vries, E. G. Eur. J. Nucl. Med. 1999, 26, 283-293.
63. (a) Preliminary studies on a common pharmacophore for Taxol, epothilone B, and diseodermolide were presented at the Alfred Benzon Symposium 42, Copenhagen, Denmark, June 8-12, 1997; Snyder, J. P. Abstracts.
64. (b) Jansen, J. M.; Koehler, K. F.; Hedberg, M. H.; Johansson, A. M.; Hacksell, U.; Nordvall, G.; Snyder. J. P. J. Chem. Inf. Comput. Sci. 1997, 37, 812-818.
65. (c) Snyder, J. P.; Xia, X.; Schestopol, M. A.; Kim, Y.; Bray, D.; Cain, M.; Liotta, D.; Koehler, K. F.; Jansen, J. M. In Rational Molecular Design in Drug Research; Liljefors, T., Jørgensen, F. S.,Krogsgaard-Larsen, P., Eds.; Munksgaard: Copenhagen, 1998; pp 115-135.
66. Murray-Rust, P.; Glusker, J. P. J. Am. Chem. Soc. 1984, 106, 1018-1025.
67. Lommerse, J. P. M.; Price, S. L.; Taylor, R. J. Comput. Chem. 1997, 18, 757-774.
68. The current version of the software is PrGen 2.0.
69. MacroModel web site: http://www.schrodinger.com/macromodel.html
70. Still, C. W.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. J. Am. Chem. Soc. 1990, 112, 6127-6129.
71. Stewart, J. J. P. MOPAC 6.0, Quantum Chemistry Program Exchange (QCPE), 455, Indiana University, Bloomington, IN 47405; http://www.chem.indiana.edu/qcpe.htm.
72. (a) Kearsley, S. K.; Smith, G. M. Tetrahedron Comput. Methodol. 1990, 3, 615-633.
73. (b) Klebe, G.; Mietzner, T.; Weber, F. J. Comput.-Aided Mol. Design 1994, 8, 751-778.
74. Ewing, T. J. A.; Kuntz, I. D. J. Comput. Chem. 1997, 18, 1175-1189.
75. Halgren, T. A. J. Comput. Chem. 1996, 17, 490-519; 520-552; 553-586; 616-641. Halgren, T. A.; Nachbar, R. B. Ibid. 1996, 17, 587- 615.
76. Halgren, T. A. J. Comput. Chem. 1996, 17, 490-519; 520-552; 553-586; 616-641. Halgren, T. A.; Nachbar, R. B. Ibid. 1996, 17, 587-615.
77. Nicolaou, K. C.; Winssinger, N.; Pastor, J.; Ninkovic, S.; Sarabia, F.; He, Y.; Vourloumis, D.; Yang, Z.; Li, T.; Ginnakakou, P.; Hamel, E. Nature 1997, 387, 268-272.